This paper presents serial cardiac-catheterization data showing spontaneous functional closure of large symptomatic defects in 3 infants. One had an associated moderate-sized patent ductus arteriosus ...
Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
May 31, 2007 (Seattle, WA) - The pivotal trial of a new device approved for the percutaneous closure of atrial septal defects (ASD)--the HELEX septal occluder (WL Gore and Associates, Flagstaff, ...
Expert Rev Cardiovasc Ther. 2007;5(6):1135-1146. Diagnosing a secundum ASD is more often than not incidental because the defect normally causes symptoms late in adult life. Echocardiography and MRI ...
NEW YORK - March 12, 2019-The Cardiovascular Research Foundation (CRF) is pleased to announce that the latest issue of Structural Heart: The Journal of the Heart Team features original research ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
An atrial septal defect is the persistence of a hole (the foramen ovale) in the wall (septum) between the right atrium and left atrium of the heart. The foramen ovale usually closes spontaneously ...
FLAGSTAFF, Ariz.- W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration's (FDA's) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ...
Please provide your email address to receive an email when new articles are posted on . Artificial intelligence effectively detected atrial septal defect on ECGs from three separate institutions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results